NY-FLEXTRADE-SYSTEMS
20.2.2024 14:01:31 CET | Business Wire | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and JonesTrading, a leading global equity brokerage & capital markets firm today announced the successful deployment of FlexOMS as the new sell-side trading platform for its equities and electronic trading businesses. The solution will also be the full-service technology platform for JonesTrading’s growing outsourced trading offering.
JonesTrading partners with over 1,500 institutions and hedge funds, providing a range of liquidity sources, electronic trading and execution management services globally. As part of its regular strategic reviews of the technology solutions and vendor relationships that serve its various business units, JonesTrading identified the need to replace its incumbent sell-side OMS solution during Q3 of 2023. Following a comprehensive evaluation of the available options in the market, the firm chose FlexTrade’s multi-asset sell-side trading order management solution, FlexOMS, as the optimal platform to expand upon their equities, outsourced, and electronic trading desks both now and in the future.
The project kicked off in 2023, with FlexOMS live and in production in record time, ultimately encompassing JonesTrading’s equities, electronic trading, and outsourced trading desk. Using FlexOMS’s open architecture and API-rich technology, the solution was also able to connect all of JonesTrading’s vital downstream systems, including reporting, accounting, best execution, and finance systems, within the allotted deadline.
Jack Garceau, Chief Technology Officer at JonesTrading noted: “Firstly, our aggressive timelines meant that we needed to work with a partner who understood our business and offered flexible yet powerful technology solutions to meet our requirements. That was essentially the baseline. Equally crucial in our decision was selecting a partner that could value-add in addition to the technology by offering the services and long-term relationships that we need to continue to build out our service offerings. To continue growing, FlexTrade was that reliable partner that could meet our business needs from a technology perspective and deliver in the contracted time frame that the project demanded.”
Rajiv Kedia, Principal & Associate Founder at FlexTrade Systems added: “We are delighted to welcome JonesTrading to the FlexOMS global client community and appreciate the confidence they placed in FlexTrade. It has been a pleasure working with the highly knowledgeable team at JonesTrading and we are happy to see this solution in place. It demonstrates clearly what can be achieved with a tight, synchronized approach between client and technology partner when implementing flexible, open OMS solutions. Our open-architecture, client-first approach has delivered cutting-edge trading technology and seamless straight-through processing to JonesTrading’s multiple business lines. We look forward to partnering further with JonesTrading to optimize and expand their use of FlexOMS to other business areas.”
About FlexTrade
FlexTrade Systems is the global leader in high-performance trading technology, including multi-asset execution and order management systems that span across equities, fixed income, foreign exchange, futures, and options. We’re recognized globally for our innovation lead by client-driven collaboration across order and execution management tools and solutions.
With a global presence in 45 countries, we work closely with both buy- and sell-side clients. Our team of over 500 dedicated software developers and industry specialists curate powerful, customized trading workflows across multiple asset classes. Our commitment to customer-centric innovation leads to breakthrough solutions that boost trading performance.
About JonesTrading
JonesTrading Institutional Services LLC is a leading global institutional trading broker dealer. Since 1975, JonesTrading's sole focus has been creating liquidity for institutional and corporate clients on an unconflicted basis. The ability to provide a secure trusted platform connecting a diverse group of market participants enables the firm to unlock liquidity, providing best-quality execution for larger and more complex trades. Member FINRA and SIPC.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220754835/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom